This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Inflammation				
Inflammation	Toll-like receptor 2 (TLR2)	<p><i>In vitro</i> and mouse studies identified TLR2 ligands that could help treat inflammatory disorders. In wild-type mice, cytokine-induced neutrophil recruitment was inhibited and host response to <i>Escherichia coli</i> bacterial challenge was delayed by the TLR2 ligand lipoteichoic acid (LTA). In wild-type mice, a synthetic TLR2 ligand containing a side chain from LTA decreased neutrophil recruitment comparably to LTA. Next steps include studying the ligands in mouse models of acute and chronic inflammation. Cleveland BioLabs Inc.'s TLR2 agonist Protectan CBLB612 is in preclinical testing for hematologic mobilization.</p> <p>SciBX 4(38); doi:10.1038/scibx.2011.1072 Published online Sept. 29, 2011</p>	Provisional U.S. patent application filed for the technology; available for licensing worldwide	<p>Long, E. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Sept. 19, 2011; doi:10.1073/pnas.1100702108</p> <p>Contact: Stephen Robbins, University of Calgary, Calgary, Alberta, Canada e-mail: srobbins@ucalgary.ca</p>